Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Long-Term Survival in Patients with HER2-Positive MBC

Breast Cancer Res Treat; ePub 2016 Aug 13; Harano, et al

Hormone receptor positivity, low burden of disease, metastasis to soft and bone tissues, and surgical management with resection of the metastatic site and the primary tumor were associated with long-term survival in patients with metastatic breast cancer (MBC) who received anti-HER2 treatment, in a recent study. The study included 1,063 patients with HER-positive (HER+) MBC diagnosed between 1994 and 2012 and treated with anti-HER2 therapy. Researchers found:

• 154 (14.5%) patients were categorized as long-term survivors (LTS); among them, 63.4% were HR-positive and 32% had de novo stage IV disease.

• Hormone receptor positivity (OR 1.69), resection of metastases (OR 2.38), and primary breast surgery in patients with de novo stage IV (OR 2.88) were associated with improved long-term survival.

• Greater number of metastatic sites (≥3 vs 1, OR 0.41) and visceral metastases (OR 0.61) were associated with poor survival.

Citation: Harano K, Lei X, Gonzalez-Angulo, AM, et al. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. [Published online ahead of print August 13, 2016]. Breast Cancer Res Treat. doi:10.1007/s10549-016-3933-6.